Index RUT P/E - EPS (ttm) -2.28 Insider Own 37.94% Shs Outstand 37.17M Perf Week 12.78%
Market Cap 3.39B Forward P/E - EPS next Y -3.79 Insider Trans -0.54% Shs Float 36.29M Perf Month 19.84%
Income -118.48M PEG - EPS next Q -0.78 Inst Own 76.98% Short Float 22.81% Perf Quarter 52.49%
Sales 0.00M P/S - EPS this Y 16.88% Inst Trans - Short Ratio 18.81 Perf Half Y -12.92%
Book/sh 13.65 P/B 4.25 EPS next Y -35.84% ROA -25.44% Short Interest 8.28M Perf Year 178.05%
Cash/sh 11.56 P/C 5.01 EPS next 5Y - ROE -26.73% 52W Range 14.19 - 72.29 Perf YTD 107.39%
Dividend Est. - P/FCF - EPS past 5Y - ROI -15.27% 52W High -19.84% Beta 2.79
Dividend TTM - Quick Ratio 27.70 Sales past 5Y 0.00% Gross Margin - 52W Low 308.35% ATR (14) 2.92
Dividend Ex-Date - Current Ratio 27.70 EPS Y/Y TTM - Oper. Margin 0.00% RSI (14) 71.10 Volatility 5.80% 5.20%
Employees - Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 85.50
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -60.56% Payout - Rel Volume 1.50 Prev Close 52.95
Sales Surprise - EPS Surprise -3.58% Sales Q/Q - Earnings Aug 12 BMO Avg Volume 440.08K Price 57.94
SMA20 17.34% SMA50 21.54% SMA200 31.11% Trades
Volume 566,375 Change 9.43%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-24 Initiated BofA Securities
Buy
$80
Dec-20-23 Initiated BTIG Research
Buy
$43
Aug-08-23 Initiated Wedbush
Outperform
$40
Aug-08-23 Initiated TD Cowen
Outperform
Aug-08-23 Initiated Stifel
Buy
$34
Aug-08-23 Initiated Jefferies
Buy
$29
Aug-08-23 Initiated Guggenheim
Buy
$29
Sep-12-24 07:00AM
Sep-09-24 07:00AM
Sep-07-24 01:45AM
Aug-24-24 01:30AM
Aug-19-24 07:00AM
06:30AM
Loading…
Aug-12-24 06:30AM
Aug-10-24 01:00AM
01:00AM
Jul-18-24 08:00AM
Jul-06-24 01:00AM
01:00AM
May-28-24 07:30AM
May-23-24 07:30AM
May-15-24 04:01PM
May-13-24 01:53PM
07:42AM
Loading…
07:42AM
07:00AM
May-10-24 10:13AM
May-08-24 01:28PM
May-06-24 08:00AM
Apr-03-24 07:49AM
Mar-28-24 11:01AM
Mar-25-24 07:00AM
07:00AM
Mar-12-24 04:01PM
Mar-07-24 06:49PM
Mar-05-24 10:53PM
(InvestorPlace) +42.07%
+12.46%
04:23PM
04:16PM
(Investor's Business Daily)
07:35AM
(Investor's Business Daily)
07:35AM
Loading…
07:35AM
(Investor's Business Daily)
06:10AM
06:00AM
06:00AM
Mar-04-24 04:01PM
Jan-02-24 07:30AM
Nov-15-23 04:44AM
Nov-13-23 07:30AM
Oct-30-23 08:00AM
Oct-23-23 02:50AM
Sep-27-23 08:42AM
Sep-14-23 07:30AM
Aug-29-23 08:00AM
Aug-28-23 07:30AM
Aug-21-23 07:30AM
Aug-10-23 02:29PM
Aug-08-23 10:02AM
Aug-07-23 07:30AM
Aug-04-23 06:30PM
Aug-02-23 07:30AM
Jul-18-23 04:01PM
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dambkowski Carl Chief Medical Officer Sep 04 '24 Sale 47.56 6,665 316,969 280,793 Sep 06 08:03 PM HENDERSON MICHAEL THOMAS Chief Executive Officer Sep 04 '24 Sale 47.62 40,000 1,904,841 1,394,487 Sep 06 08:02 PM HENDERSON MICHAEL THOMAS Officer Sep 04 '24 Proposed Sale 47.62 40,000 1,904,848 Sep 04 01:35 PM Henderson Jane Chief Financial Officer Aug 23 '24 Sale 48.26 6,000 289,560 200,871 Aug 23 08:05 PM JANE V HENDERSON Officer Aug 23 '24 Proposed Sale 48.26 6,000 289,570 Aug 23 04:09 PM Dambkowski Carl Chief Medical Officer Aug 07 '24 Sale 40.67 7,335 298,336 287,458 Aug 09 08:05 PM HENDERSON MICHAEL THOMAS Chief Executive Officer Aug 07 '24 Sale 40.62 40,000 1,624,764 1,434,487 Aug 09 08:05 PM HENDERSON MICHAEL THOMAS Officer Aug 07 '24 Proposed Sale 40.62 40,000 1,624,784 Aug 07 01:18 PM HENDERSON MICHAEL THOMAS Chief Executive Officer Jul 05 '24 Sale 37.26 15,000 558,900 1,474,487 Jul 05 08:01 PM Dambkowski Carl Chief Medical Officer Jul 03 '24 Sale 37.60 5,995 225,418 294,793 Jul 05 08:01 PM
Index RUT P/E - EPS (ttm) -3.41 Insider Own 16.33% Shs Outstand 69.43M Perf Week 1.43%
Market Cap 1.93B Forward P/E - EPS next Y -3.81 Insider Trans -3.17% Shs Float 58.09M Perf Month 5.24%
Income -204.18M PEG - EPS next Q -0.88 Inst Own 98.53% Short Float 12.24% Perf Quarter 19.53%
Sales 0.00M P/S - EPS this Y -24.85% Inst Trans 15.46% Short Ratio 11.04 Perf Half Y 6.90%
Book/sh 11.53 P/B 2.40 EPS next Y -5.57% ROA -26.71% Short Interest 7.11M Perf Year -42.94%
Cash/sh 10.95 P/C 2.53 EPS next 5Y - ROE -28.87% 52W Range 11.25 - 51.81 Perf YTD 18.76%
Dividend Est. - P/FCF - EPS past 5Y 1.03% ROI -24.49% 52W High -46.48% Beta -0.26
Dividend TTM - Quick Ratio 24.89 Sales past 5Y 0.00% Gross Margin - 52W Low 146.49% ATR (14) 1.28
Dividend Ex-Date - Current Ratio 24.89 EPS Y/Y TTM -33.20% Oper. Margin 0.00% RSI (14) 59.47 Volatility 5.23% 4.73%
Employees 56 Debt/Eq 0.05 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 48.62
Option/Short Yes / Yes LT Debt/Eq 0.04 EPS Q/Q -35.07% Payout - Rel Volume 0.64 Prev Close 28.00
Sales Surprise - EPS Surprise 2.37% Sales Q/Q - Earnings Aug 09 BMO Avg Volume 643.93K Price 27.73
SMA20 4.23% SMA50 5.70% SMA200 18.27% Trades
Volume 352,068 Change -0.96%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-24 Resumed BofA Securities
Neutral
$30
Sep-19-23 Initiated Cantor Fitzgerald
Overweight
$69
Aug-28-23 Initiated UBS
Buy
$83
Jan-27-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$40 → $65
Sep-14-22 Upgrade Evercore ISI
In-line → Outperform
$10 → $50
Oct-19-21 Downgrade Morgan Stanley
Overweight → Equal-Weight
$27
Sep-10-21 Initiated BofA Securities
Buy
$40
Feb-26-21 Initiated Guggenheim
Buy
$54
Sep-10-20 Initiated Morgan Stanley
Overweight
$70
Jul-20-20 Reiterated H.C. Wainwright
Buy
$45 → $62
Jul-07-20 Initiated Chardan Capital Markets
Buy
$79
Jul-01-20 Reiterated H.C. Wainwright
Buy
$33 → $45
Mar-02-20 Initiated H.C. Wainwright
Buy
$33
Feb-10-20 Initiated Canaccord Genuity
Buy
$36
Jul-15-19 Initiated ROTH Capital
Buy
$34
Jul-15-19 Initiated JP Morgan
Overweight
$28
Jul-15-19 Initiated Jefferies
Buy
$28
Jul-15-19 Initiated Evercore ISI
Outperform
$35
Show Previous Ratings
Sep-12-24 01:12AM
Sep-09-24 07:00AM
Sep-05-24 12:02AM
Sep-02-24 05:22PM
Aug-28-24 04:05PM
02:53PM
Loading…
Aug-09-24 02:53PM
07:00AM
Jul-16-24 12:00PM
Jun-28-24 10:40AM
Jun-24-24 01:04PM
Jun-21-24 11:06AM
Jun-19-24 02:45PM
Jun-17-24 10:23AM
Jun-13-24 03:57PM
09:00AM
07:00AM
Loading…
Jun-11-24 07:00AM
Jun-10-24 10:14AM
Jun-08-24 08:15AM
Jun-06-24 10:39AM
Jun-03-24 09:57AM
May-30-24 09:16PM
May-29-24 07:00AM
May-23-24 02:12PM
May-15-24 09:26AM
May-12-24 09:01PM
May-10-24 01:54PM
07:45AM
07:00AM
May-08-24 07:00AM
Apr-30-24 08:00AM
06:00AM
Loading…
Apr-22-24 06:00AM
Mar-20-24 01:32PM
12:58PM
Mar-18-24 07:00AM
(The Wall Street Journal)
Mar-08-24 04:02PM
Mar-07-24 04:01PM
Mar-06-24 11:54PM
Mar-05-24 09:13PM
02:12PM
Mar-04-24 04:21PM
04:04PM
(Investor's Business Daily)
12:30PM
(The Wall Street Journal)
11:59AM
09:23AM
(Investor's Business Daily)
06:22AM
06:09AM
06:00AM
04:00AM
Mar-01-24 09:55AM
Feb-29-24 08:00AM
07:00AM
Feb-06-24 10:48AM
Feb-05-24 09:55AM
Jan-30-24 09:40AM
Jan-03-24 08:15AM
Dec-18-23 07:00AM
Dec-13-23 03:06AM
Dec-05-23 01:34PM
12:36PM
Nov-14-23 07:21PM
Nov-13-23 07:00AM
Nov-10-23 08:57AM
Nov-08-23 07:00AM
Oct-17-23 04:05PM
Oct-12-23 04:38PM
08:24AM
Oct-11-23 05:35PM
11:11AM
Oct-10-23 04:13PM
04:03PM
(Investor's Business Daily)
12:10PM
(Associated Press Finance)
11:44AM
10:37AM
09:29AM
07:15AM
07:00AM
Oct-09-23 04:05PM
Oct-05-23 07:01AM
Oct-04-23 08:00AM
Sep-29-23 12:43PM
Sep-27-23 09:24PM
Sep-14-23 07:56AM
Aug-31-23 07:00AM
Aug-28-23 07:00AM
Aug-11-23 06:00AM
Jul-11-23 09:02AM
Jul-10-23 09:32AM
09:29AM
08:58AM
Jul-07-23 08:00AM
(The Wall Street Journal)
07:46AM
Jul-03-23 11:20AM
10:25AM
Jul-01-23 09:00AM
Jun-29-23 10:04AM
09:59AM
09:18AM
Jun-28-23 10:53AM
Jun-27-23 01:47PM
Jun-26-23 11:23AM
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Yale Catriona Chief Development Officer Sep 18 '24 Option Exercise 0.61 3,871 2,381 79,165 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 16 '24 Option Exercise 0.61 2,485 1,528 77,779 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 17 '24 Option Exercise 0.61 2,037 1,253 77,331 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 18 '24 Sale 27.56 3,871 106,685 75,294 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 16 '24 Sale 27.52 2,485 68,375 75,294 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 17 '24 Sale 27.55 2,037 56,115 75,294 Sep 18 09:19 PM CATRIONA YALE Officer Sep 16 '24 Proposed Sale 27.34 13,893 379,835 Sep 16 04:34 PM Young Jonathan Chief Operating Officer Sep 10 '24 Sale 26.18 568 14,870 236,286 Sep 13 05:16 PM Yale Catriona Chief Development Officer Sep 10 '24 Sale 26.18 637 16,677 75,294 Sep 13 05:14 PM White William Richard Chief Financial Officer Sep 10 '24 Sale 26.18 639 16,729 41,152 Sep 13 05:13 PM Rolph Timothy Chief Scientific Officer Sep 10 '24 Sale 26.18 537 14,059 180,705 Sep 13 05:11 PM Cheng Andrew President and CEO Sep 10 '24 Sale 26.18 1,738 45,501 605,417 Sep 13 05:10 PM Young Jonathan Chief Operating Officer Sep 03 '24 Sale 26.72 5,000 133,588 236,854 Sep 05 04:08 PM Yale Catriona Chief Development Officer Sep 03 '24 Option Exercise 0.61 949 584 76,880 Sep 05 04:05 PM Yale Catriona Chief Development Officer Sep 03 '24 Sale 27.61 949 26,206 75,931 Sep 05 04:05 PM White William Richard Chief Financial Officer Aug 26 '24 Option Exercise 14.57 75,159 1,095,329 74,462 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 27 '24 Option Exercise 21.09 23,175 488,761 64,966 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 26 '24 Sale 27.21 75,159 2,045,152 41,791 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 27 '24 Sale 26.41 23,175 612,098 41,791 Aug 29 04:30 PM Yale Catriona Chief Development Officer Aug 23 '24 Option Exercise 0.61 8,851 5,443 84,782 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 26 '24 Option Exercise 0.61 5,200 3,198 81,131 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 23 '24 Sale 27.53 8,851 243,641 75,931 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 26 '24 Sale 27.51 5,200 143,073 75,931 Aug 28 11:11 AM White William Richard Officer Aug 26 '24 Proposed Sale 27.46 98,334 2,700,252 Aug 26 04:32 PM CATRIONA YALE Officer Aug 23 '24 Proposed Sale 26.11 15,000 391,650 Aug 23 04:27 PM Cheng Andrew President and CEO Aug 16 '24 Option Exercise 0.61 24,538 15,091 607,155 Aug 20 11:45 AM Young Jonathan Chief Operating Officer Aug 01 '24 Sale 26.75 5,000 133,756 241,854 Aug 02 09:32 PM White William Richard Chief Financial Officer Jul 24 '24 Option Exercise 7.01 139,083 974,833 180,874 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 25 '24 Option Exercise 7.01 22,272 156,104 64,063 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 23 '24 Option Exercise 7.01 500 3,504 42,291 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 24 '24 Sale 26.98 139,083 3,753,041 41,791 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 25 '24 Sale 27.61 22,272 614,820 41,791 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 23 '24 Sale 28.01 500 14,005 41,791 Jul 25 05:54 PM White William Richard Chief Financial Officer Jul 16 '24 Option Exercise 7.01 29,803 208,889 76,602 Jul 18 09:41 PM White William Richard Chief Financial Officer Jul 16 '24 Sale 28.04 34,811 976,274 41,791 Jul 18 09:41 PM Young Jonathan Chief Operating Officer Jul 01 '24 Sale 23.40 5,000 117,020 246,854 Jul 02 06:55 PM Young Jonathan Chief Operating Officer Jun 11 '24 Sale 22.64 2,516 56,965 250,790 Jun 13 06:13 PM Yale Catriona Chief Development Officer Jun 11 '24 Sale 22.64 2,825 63,961 74,867 Jun 13 06:11 PM White William Richard Chief Financial Officer Jun 11 '24 Sale 22.64 2,831 64,094 46,799 Jun 13 06:09 PM Rolph Timothy Chief Scientific Officer Jun 11 '24 Sale 22.64 2,380 53,886 180,178 Jun 13 06:06 PM Lamy Patrick Senior VP, Commercial Strategy Jun 11 '24 Sale 22.64 569 12,883 18,562 Jun 13 06:04 PM Cheng Andrew President and CEO Jun 11 '24 Sale 22.64 7,894 178,728 581,553 Jun 13 06:01 PM Young Jonathan Chief Operating Officer Jun 03 '24 Sale 19.29 5,000 96,440 253,306 Jun 05 05:05 PM Young Jonathan Chief Operating Officer May 01 '24 Sale 20.15 5,000 100,750 258,306 May 02 09:07 PM Young Jonathan Chief Operating Officer Apr 01 '24 Sale 24.38 5,000 121,913 263,306 Apr 03 06:55 PM Yale Catriona Chief Development Officer Mar 13 '24 Sale 28.33 723 20,483 77,692 Mar 15 04:45 PM White William Richard Chief Financial Officer Mar 13 '24 Sale 28.33 724 20,511 49,630 Mar 15 04:44 PM Cheng Andrew President and CEO Mar 13 '24 Sale 28.33 1,969 55,782 589,447 Mar 15 04:43 PM Young Jonathan Chief Operating Officer Mar 13 '24 Sale 28.33 651 18,443 268,306 Mar 15 04:42 PM Rolph Timothy Chief Scientific Officer Mar 13 '24 Sale 28.33 619 17,536 182,558 Mar 15 04:42 PM Cheng Andrew President and CEO Mar 04 '24 Option Exercise 17.17 75,000 1,288,062 666,416 Mar 06 08:14 PM Cheng Andrew President and CEO Mar 04 '24 Sale 32.87 75,000 2,465,063 591,416 Mar 06 08:14 PM Yale Catriona Chief Development Officer Mar 04 '24 Option Exercise 13.96 20,646 288,124 99,061 Mar 06 08:13 PM Yale Catriona Chief Development Officer Mar 04 '24 Sale 35.49 20,646 732,727 78,415 Mar 06 08:13 PM Young Jonathan Chief Operating Officer Mar 01 '24 Option Exercise 0.61 83,321 51,242 268,957 Mar 05 05:16 PM Cheng Andrew President and CEO Jan 02 '24 Option Exercise 0.61 40,000 24,600 590,911 Jan 03 05:00 PM Young Jonathan Chief Operating Officer Dec 27 '23 Option Exercise 6.36 5,414 34,433 190,545 Dec 29 08:30 PM Young Jonathan Chief Operating Officer Dec 27 '23 Sale 24.00 5,414 129,936 185,131 Dec 29 08:30 PM Yale Catriona Chief Development Officer Dec 14 '23 Sale 20.76 597 12,394 77,910 Dec 18 08:49 PM White William Richard Chief Financial Officer Dec 14 '23 Sale 20.76 611 12,684 50,354 Dec 18 08:40 PM Young Jonathan Chief Operating Officer Dec 14 '23 Sale 20.76 543 11,273 185,131 Dec 18 08:39 PM Cheng Andrew President and CEO Dec 14 '23 Sale 20.76 1,628 33,797 550,911 Dec 18 08:37 PM Rolph Timothy Chief Scientific Officer Dec 14 '23 Sale 20.76 514 10,671 182,672 Dec 18 08:29 PM Graham G. Walmsley Director Dec 08 '23 Buy 19.83 100,000 1,982,940 800,000 Dec 11 09:06 PM Cheng Andrew President and CEO Dec 08 '23 Option Exercise 6.36 12,873 81,872 473,871 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 11 '23 Option Exercise 6.36 7,405 47,096 559,944 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 07 '23 Option Exercise 6.36 6,700 42,612 467,698 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 08 '23 Sale 20.01 12,873 257,571 460,998 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 11 '23 Sale 20.02 7,405 148,273 552,539 Dec 11 08:59 PM Cheng Andrew President and CEO Dec 07 '23 Sale 20.02 6,700 134,125 460,998 Dec 11 08:59 PM Graham G. Walmsley Director Dec 01 '23 Buy 16.99 50,000 849,730 700,000 Dec 05 08:37 AM Graham G. Walmsley Director Nov 30 '23 Buy 16.90 50,000 844,835 650,000 Dec 05 08:37 AM Young Jonathan Chief Operating Officer Nov 17 '23 Sale 14.68 30,000 440,259 153,177 Nov 21 05:30 PM Cheng Andrew President and CEO Oct 02 '23 Option Exercise 6.36 25,000 159,000 485,998 Oct 04 08:41 PM Cheng Andrew President and CEO Oct 02 '23 Sale 47.91 25,000 1,197,827 460,998 Oct 04 08:41 PM Young Jonathan Chief Operating Officer Oct 02 '23 Option Exercise 21.10 490 10,339 183,667 Oct 04 08:33 PM Young Jonathan Chief Operating Officer Oct 02 '23 Sale 51.10 490 25,039 183,177 Oct 04 08:33 PM Yale Catriona Chief Development Officer Sep 21 '23 Option Exercise 6.36 5,000 31,800 51,010 Sep 25 08:31 PM Yale Catriona Chief Development Officer Sep 21 '23 Sale 48.07 5,000 240,356 46,010 Sep 25 08:31 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
